Medtronic plc(MDT)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Medtronic plc (MDT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDT at 68.5/100 on a 32-signal composite quality model, placing it at rank #317 of 2,961 stocks — the top 25% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Medtronic plc reports quarterly revenue of $9.8B, net income of $1.5B, an operating margin of 18.1%. Top institutional holders of MDT by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. MDT trades on the NYSE exchange and files with the SEC under CIK 1613103. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medtronic plc directly from SEC EDGAR.
AI Quality Score
68.5/100
AI Rank
#317
Revenue
$9.8B
Net Income
$1.5B
Free Cash Flow
$1.3B
Operating Margin
18.1%
MDT key financials by period
Medtronic plc reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2026
10-K
$36.4B
$4.8B
17.8%
FY 2025
10-K
$33.5B
$4.7B
17.8%
FY 2024
10-K
$32.4B
$3.7B
15.9%
FY 2023
10-K
$31.2B
$3.8B
17.6%
FY 2022
10-K
$31.7B
$5.0B
18.1%
FY 2021
10-K
$30.1B
$3.6B
14.9%
Institutions holding MDT
Institutional investors reporting a position in Medtronic plc on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-09-03 — Q1 FY2027 (quarter ended July 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Medtronic reported Q1 revenue of $9.8B (+14% YoY) driven by Cardiovascular (+20%), Neuroscience (+10%), and Medical Surgical (+10%) growth; diluted EPS $1.14 on GAAP basis, $1.45 non-GAAP.
Biggest Revenue Drivers
Cardiovascular$3.9B+20% YoY
Growth across most divisions; Electrophysiology Therapies +30% driven by pulsed field ablation and Cardiac Rhythm Management; Interventional Cardiology Therapies +7%; CardioVascular Surgery +9%; Peripheral Vascular Health +12%.
Neuroscience$2.7B+10% YoY
Cranial & Spinal Technologies +13% from AiBLE ecosystem adoption; Specialty Therapies +10% from Altaviva and Neurovascular growth; Neuromodulation +5%.
Biggest Revenue Drivers
Total revenue: $9.8B+14% YoY
Cardiovascular$3.9B+20% YoY
Growth across most divisions; Electrophysiology Therapies +30% driven by pulsed field ablation and Cardiac Rhythm Management; Interventional Cardiology Therapies +7%; CardioVascular Surgery +9%; Peripheral Vascular Health +12%.
Neuroscience$2.7B+10% YoY
Cranial & Spinal Technologies +13% from AiBLE ecosystem adoption; Specialty Therapies +10% from Altaviva and Neurovascular growth; Neuromodulation +5%.
Medical Surgical$2.3B+10% YoY
Surgical & Endoscopy +9% from LigaSure, V-Loc, ProGrip, and Hugo RAS; Acute Care & Monitoring +14% from Nellcor, McGRATH MAC, and Capnography.
Diabetes$843M+17% YoY
U.S. growth from MiniMed Flex commercial launch; international growth from continued MiniMed 780G AID system adoption.
Largest Expense Items
Selling, general, and administrative expense$3.2B+14% YoY
Increase driven by selling expenses in line with sales growth and new product launches and commercialization activities.
Research and development expense$771M+6% YoY
Continued commitment to innovation across therapy solutions.
Amortization of intangible assets$412M-10% YoY
Decrease primarily from $45M accelerated amortization on Cardiovascular intangible assets in prior year.
Margins: Gross margin as a percent of net sales remained flat year-over-year at approximately 65%, supported by favorable pricing and cost-down initiatives that offset unfavorable product mix. Operating profit increased 22% to $1.8B, reflecting strong revenue growth and operating leverage.
Watch Items from the Filing
Hernia mesh litigation: as of August 5, 2026, ~10,500 plaintiffs across coordinated proceedings; first MDL trial verdict on August 4, 2026 awarded $88M in damages; Company has not recorded a liability as ultimate loss remains uncertain pending post-trial challenges and appeals.
Applied Medical antitrust litigation: jury verdict in February 2026 awarded $382M (auto-trebled to ~$1.1B); Company believes award inconsistent with law and plans appeal; ultimate loss not probable and not accrued pending appellate outcome.
MiniMed separation: company retains 90.03% ownership post-March 2026 IPO; plans to complete divestiture within fiscal year 2027; $201M restructuring costs incurred to date with $300-500M expected total charges through fiscal 2029.
Portfolio restructuring: Cardiovascular divisions reorganized into four new divisions (EPT, ICT, CVS, PVH); Diabetes no longer a reportable segment; product line moved from Medical Surgical to Neuroscience, reflecting strategic repositioning.
Acquisitions completed: Scientia Vascular ($681M, June 2026) for neurovascular access; SPR Therapeutics ($654M, July 2026) for peripheral nerve stimulation; CathWorks ($718M, April 2026) for coronary diagnostics.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
